Handling adverse events in clinical trials can be quite complicated, as legal requirements and the organization of the pharmaceutical company concerned have to be considered. The shared responsibilities within the company, especially if it is an international one, lead to complex processes of information flow and to the necessity for internal regulations. Both can be reflected by the definition of the respective database(s). Problems of the information system are described; possibilities and aspects for a solution are given.
Good clinical practice for trials on medicinal products in the EC, Glossary. European Community—CPMP. III/3976/88;1990.
2.
BethgeHEmpfehlungen zur Ermittlung, Dokumentation, Erfassung und Bewertung unerwünschter Ereignisse im Rahmen der klinischen Prüfung von Arzneimitteln. Arzneimittel-Forschung/Drug Research. 1989;39: 1294–1300.
3.
KarchFELasagnaL. Adverse drug reactions—a critical review. JAMA. 1975;234: 1236–1241.
4.
Causality classification in pharmacovigilance in the EC. European Community—CPMP. III/3445/91;1991.
5.
HönigUMuschaweckLSteinackerA. Konzeption und Realisierung eines EDV-gestützten Informations systems zur Verbesserung der Arzneimittelsicherheit in der pharmazeutischen Industrie. Pharm Ind. 1991;53: 423–425.
6.
TangreaJAAdrianzaMEMcAdamsM. A method for the detection and management of adverse events in clinical trials. Drug Inf J.1991;25: 63–80.
7.
CurranCFBawaO. Implementation of a worldwide drug safety surveillance system. Drug Inf J.1990;24: 605–614.
8.
JustizBundesministerGesetz über den Verkehr mit Arzneimitteln (AMG), §§31(2), 49(6); 1990.
